[1] Guo H, Zhang X, Chen Q, et al. miR-132 suppresses the migration and invasion of lung cancer cells by blocking USP9X-induced epithelial-mesenchymal transition. Am J Transl Res, 2018, 10: 224-234.
[2] 魏本尊,李捷,沈超,等.去泛素化酶USP9X在etoposide促结肠癌细胞SW620凋亡中的作用研究.中国现代普通外科进展,2014,17:8-11.
[3] 程艳,刘钧.去泛素化酶USP9X在宫颈鳞癌中的表达及临床意义.现代肿瘤医学,2016,24:2947-2950.
[4] Cui J, Sun W, Hao X,et al. EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells. Cancer Cell Int, 2015, 15: 4.
[5] 杜海磊,杨卫平,陈聆,等.索拉非尼抑制肝癌细胞增殖中自噬的作用及其机制.外科理论与实践,2011,16:270-274.
[6] 陆谦,陈钟.泛素蛋白酶体系统与肝细胞肝癌治疗的研究进展.南通大学学报(医学版),2018,38:115-119.
[7] Deshmukh R,Dou P. Proteasome inhibitors induce AMPK activation via CaMKKβ in human breast cancer cells.Breast Cancer Res. Treat,2015,153:79-88.
[8] 胡惠雯,汤成泳,蒋清虎,等.USP9X低表达通过下调Mcl-1促进肝癌细胞凋亡.中国细胞生物学学报,2014,36:913-919.
[9] 畅建平,杨艳梅,张新宇.细胞自噬在肝癌发生发展中的作用.肿瘤研究与临床,2014,26:358-360.
[10] 迟强,侯鲁强,刘军伟,等.塞来昔布诱导HePG2人肝癌细胞周期阻滞及细胞自噬的研究.中国生化药物杂志,2017,37:51-54. |
